SLAMF1 CRISPR/Cas9 KO Plasmid (canine): sc-437301
- Target species: canine
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- SLAMF1 CRISPR/Cas9 Knockout (KO) Plasmid (canine) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the SLAMF1 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
SLAMF1 CRISPR/Cas9 KO Plasmid (canine) | sc-437301 | 20 µg | $397.00 |
Overview
SLAMF1 (CD150) is a cell-surface immunoreceptor of the SLAM family expressed primarily on activated T and B lymphocytes, dendritic cells, and other hematopoietic populations, where it coordinates immune synapse formation and modulates cytokine production. Through homotypic binding and adaptor interactions with SAP/SH2D1A and downstream kinases, SLAMF1 influences signaling networks that intersect with TCR/BCR activation, MAPK, PI3K–AKT, and NF-κB pathways to shape lymphocyte activation and differentiation. In canine immunology, SLAMF1 serves as a marker of immune activation and can impact antiviral responses, leukocyte cross-talk, and inflammatory regulation. Altered SLAMF1 signaling has been linked broadly to immune dysregulation and lymphoproliferative phenotypes, making it relevant for mechanistic studies of host defense and immune-mediated disease models.
SLAMF1 CRISPR/Cas9 KO Plasmid (canine) is a pool of plasmids designed for targeted disruption of the gene in canine cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish SLAMF1 protein expression.
This CRISPR knockout system enables efficient generation of -deficient cell models for investigation of SLAMF1 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting exon(s) critical for SLAMF1 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by SLAMF1 CRISPR/Cas9 KO Plasmid (canine) and SLAMF1 CRISPR/Cas9 KO Plasmid (canine2) target distinct sites within the locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by SLAMF1 HDR Plasmid (canine) and SLAMF1 HDR Plasmid (canine2) contain a puromycin resistance cassette and an RFP reporter flanked by homology arms to support homology-directed repair at defined target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.